TriAgenics Secures $3M Series B Investment to Transform Wisdom Tooth Extraction Outcomes

TriAgenics is excited to announce a major breakthrough in our mission to transform oral health care through innovation and research. We have successfully raised $3,000,000 in our latest funding round—a significant milestone that reinforces our commitment to eliminating the risk, disease, and pain associated with wisdom tooth extraction. As an oral health research and development firm, TriAgenics has long pursued breakthrough solutions to common yet challenging dental procedures. This infusion of capital will allow us to expand our research initiatives, enhance our development of revolutionary treatment protocols, and bring advanced, minimally invasive technologies to patients in need. By furthering our commitment to patient safety and improved recovery outcomes, the new funding is set to accelerate our timeline for clinical trials and streamline the transition from laboratory research to widespread clinical application. We are poised to leverage these resources to attract top talent, invest in cutting-edge equipment, and foster strategic partnerships that drive forward-thinking innovations in oral health care. Ultimately, the funding will not only enhance our ability to mitigate the inherent risks of wisdom tooth extraction but also contribute to a broader vision of preventative care and improved quality of life for patients across the globe. We are grateful to our investors and partners for believing in our vision and supporting our efforts to redefine dental care. As we embark on this transformative journey, TriAgenics remains dedicated to bridging the gap between advanced research and practical, life-changing applications that ensure safer, more efficient, and patient-centered dental solutions.